Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Liabilities and Shareholders Equity (2022 - 2025)

Axsome Therapeutics' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $689.8 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 21.34% year-over-year to $689.8 million; the TTM value through Dec 2025 reached $2.6 billion, up 16.71%, while the annual FY2025 figure was $689.8 million, 21.34% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $689.8 million at Axsome Therapeutics, up from $669.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $689.8 million in Q4 2025 and bottomed at $88.6 million in Q1 2022.
  • The 4-year median for Liabilities and Shareholders Equity is $565.0 million (2024), against an average of $496.8 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 339.45% in 2023 before it decreased 10.37% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $331.5 million in 2022, then soared by 77.46% to $588.2 million in 2023, then decreased by 3.36% to $568.5 million in 2024, then grew by 21.34% to $689.8 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Liabilities and Shareholders Equity are $689.8 million (Q4 2025), $669.2 million (Q3 2025), and $639.8 million (Q2 2025).